Latest Healthtech Startup Funding Rounds
Companies building technology for healthcare delivery, diagnosis, clinical workflows and patient access.
- Rounds
- 744 Jan 1 – Oct 24, 2026
- Disclosed funding
- $25.3B 606 disclosed amounts
- Median round
- $16M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| IL Isomorphic LabsCompany profile Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas | $2.1B | Series B | Healthtech, Biotech | United Kingdom | Investors | |
| B BasataCompany profile Deploys AI agents to automate healthcare admin workflows including referrals, intake, and scheduling Deploys AI agents to automate healthcare admin workflows including referrals, intake, and scheduling | $21M | Series A | Healthtech | United States | Investors | |
| P ParcelBioCompany profile Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology Develops potent and durable mRNA medicines using the APEXm platform for autoimmune and oncology | $13M | Seed | Healthtech, Biotech | United States | Investors | |
| S SediventionCompany profile Develops minimally invasive one-time cryoablation therapy for obesity via balloon catheter Develops minimally invasive one-time cryoablation therapy for obesity via balloon catheter | €2.9M | Seed | Healthtech | Germany | Investors | |
| C CellCentricCompany profile Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma | $220M | Series DSeries C+ | Healthtech, Biotech | United Kingdom | Investors | |
| M MOSH makes protein bars marketed for brain health. | $13M | Series A | Healthtech, Foodtech | United States | Investors | |
| KB Kanvas BiosciencesCompany profile Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy | $48M | Series A | Healthtech, Biotech | United States | Investors | |
| MN Maurice & NoraCompany profile Connects families and seniors with students for non-medical in-home assistance via AI-matched platform Connects families and seniors with students for non-medical in-home assistance via AI-matched platform | €1M | Seed | Healthtech | Belgium | Investors | |
| LT LTZ TherapeuticsCompany profile LTZ Therapeutics develops cancer immunotherapies that target myeloid biology. LTZ Therapeutics develops cancer immunotherapies that target myeloid biology. | $38M | Undisclosed | Healthtech, Biotech | United States | Investors | |
| MP Modicus PrimeCompany profile Builds AI compliance software enabling audit-ready AI deployment for pharmaceutical and regulated industries Builds AI compliance software enabling audit-ready AI deployment for pharmaceutical and regulated industries | $4.5M | Undisclosed | Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1General Catalyst
Baba, Disha (formerly Curelink), Thatch
23rounds2led - 2Y Combinator (YC)
Vitalize, Angle Health, Metriport
21rounds0led - 3Alumni Ventures
MintNeuro, Evvy, Hopscotch Primary Care
13rounds0led - 4Andreessen Horowitz (a16z)
Sharp Performance, General Medicine, Devoted Health
12rounds2led - 5Khosla Ventures
Even Healthcare, Abby Care, Rightway
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.